Treatment of Muckle-Wells syndrome: Analysis of two IL-1-blocking regimens

Arthritis Research and Therapy

Volumn 15, Issue 3, 2013, Pages

  Kuemmerle Deschner, Jasmin B ^a   Wittkowski, Helmut ^b   Tyrrell, Pascal N ^c   Koetter, Ina ^a   Lohse, Peter ^d   Ummenhofer, Katharina ^a   Reess, Fabian ^a   Hansmann, Sandra ^a   Koitschev, Assen ^e   Deuter, Christoph ^a   Bialkowski, Anja ^a   Foell, Dirk ^f   Benseler, Susanne M ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Institut fuer Labormedizin   (Germany)

^e OLGAHOSPITAL   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

anakinra; autoinflammatory fever syndromes; canakinumab; CIAS1; interleukin 1 inhibition; Muckle Wells syndrome; mutation; NLRP3; S100A12

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CRYOPYRIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INJECTION SITE REACTION; MALE; MUCKLE WELLS SYNDROME; OBSERVATIONAL STUDY; OPEN STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; ADOLESCENT; CHILD; CINCA SYNDROME; DRUG ANTAGONISM; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878246239     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4237     Document Type: Article

References (37)

1. Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ, Pelkonnen P, Chevrant-Breton J, Ansell BM. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome: a specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987, 66:57-68.
2. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002, 46:3340-3348. 10.1002/art.10688, 12483741.
3. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305. 10.1038/ng756, 11687797.
4. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005, 17:586-599. 10.1097/bor.0000174210.78449.6b, 16093838.
5. Shinkai K, McCalmont TH, Leslie KS. Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 2008, 33:1-9.
6. Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440:233-236. 10.1038/nature04517, 16407888.
7. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232. 10.1038/nature04515, 16407890.
8. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241. 10.1038/nature04516, 16407889.
9. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galan JE, Askenase PW, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24:317-327. 10.1016/j.immuni.2006.02.004, 16546100.
10. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011, 41:1203-1217. 10.1002/eji.201141550, 21523780.
11. Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2011, 167:391-404.
12. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325. 10.1016/S1074-7613(04)00046-9, 15030775.
13. Janssen R, Verhard E, Lankester A, Ten Cate R, van Dissel JT. Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004, 50:3329-3333. 10.1002/art.20494, 15476236.
14. Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962, 31:235-248.
15. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50:607-612. 10.1002/art.20033, 14872505.
16. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371. 10.1056/NEJMoa070265, 17554117.
17. Miranda LP, Tao T, Jones A, Chernushevich I, Standing KG, Geczy CL, Alewood PF. Total chemical synthesis and chemotactic activity of human S100A12 (EN-RAGE). FEBS Lett 2001, 488:85-90. 10.1016/S0014-5793(00)02392-9, 11163801.
18. Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der Poll T, Hoidal JR, Roth J, Foell D. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007, 35:1369-1375. 10.1097/01.CCM.0000262386.32287.29, 17414728.
19. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004, 50:1286-1295. 10.1002/art.20125, 15077313.
20. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Fruhwald MC, Dassmann S, Pham TH, Roth J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008, 58:3924-3931. 10.1002/art.24137, 2680303, 19035478.
21. Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 2010, 69:677-682. 10.1136/ard.2009.114363, 19762364.
22. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452. 10.1002/art.23687, 18668535.
23. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, Pucino F, Wesley RA, Papadopoulos JH, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008, 58:2432-2442. 10.1002/art.23620, 2875198, 18668591.
24. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425. 10.1056/NEJMoa0810787, 19494217.
25. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583-2584. 10.1056/NEJM200306193482523, 12815153.
26. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010, 62:258-267.
27. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, Anderson JP, Wanderer AA, Firestein GS. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785. 10.1016/S0140-6736(04)17401-1, 15541451.
28. Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, Churchman SM, McDermott MF, Hawkins PN. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008, 12:8-16.
29. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592. 10.1056/NEJMoa055137, 16899778.
30. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, Lohse P, Koitchev A, Deuter C, Foell D, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011, 63:840-849. 10.1002/art.30149, 21360513.
31. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624. 10.1002/art.10141, 11920396.
32. Kummerle-Deschner JB, Tyrrell PN, Reess F, Kotter I, Lohse P, Girschick H, Huemer C, Horneff G, Haas JP, Koitschev A, et al. Risk factors for severe Muckle-Wells syndrome. Arthritis Rheum 2010, 62:3783-3791. 10.1002/art.27696, 20722029.
33. Kuemmerle-Deschner JB, Lohse P, Koetter I, Dannecker GE, Reess F, Ummenhofer K, Koch S, Tzaribachev N, Bialkowski A, Benseler SM. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome: description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther 2011, 13:R196. 10.1186/ar3526, 3334646, 22146561.
34. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003, 52:847-853. 10.1136/gut.52.6.847, 1773692, 12740341.
35. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2095-2102. 10.1136/ard.2011.152728, 21859692.
36. Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soyturk M, Akar S, Tunca M, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006, 45:746-750.
37. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004, 50:3762-3771. 10.1002/art.20631, 15593206.